The tie up allows GNS to use clinical and molecular information from a BMS clinical trial while using its own supercomputer-driven reverse-engineering and forward-simulation (REFS) platform for creating computer models to identify key molecular mechanisms.
GNS executive vice president and co-founder Iya Khalil said this is the first step in building an advanced in silico research paradigm that may enable development of new therapies based directly on human data, and address the needs of patients with particular genetics and molecular phenotypes, ultimately enabling the optimization of individualized patient outcomes.